MENU
AZTA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

AZTA stock forecast, quote, news & analysis

Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage... Show more

AZTA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Why Is Azenta (AZTA) Stock Down -23.82% Today?

Key Takeaways

  • AZTA shares plunged 23.82% to close at $18.75 from the previous close of $24.61.
  • Primary catalyst: Q2 fiscal 2026 earnings miss, with revenue of $145 million missing estimates of $148.75 million and non-GAAP EPS loss of $0.04 versus expected $0.11 profit.
  • Secondary drivers: $149 million non-cash goodwill impairments, gross margin contraction to 42.8%, and lowered FY2026 guidance for organic revenue to -2% to +1%.
  • Trading volume elevated at 964,691 shares versus average of around 900,000, indicating strong selling pressure amid healthcare sector softness.
  • Move diverged negatively from broader biotech ETFs like IBB and XBI, which saw milder declines.
  • Traders watching execution improvements, Multiomics transformation, and Q3 results in August.

Opening Summary

Azenta, Inc. (AZTA), a provider of sample management and multiomics solutions for the life sciences industry, saw its stock plummet 23.82% in the most recent completed trading session. Shares closed at $18.75, down sharply from the prior close of $24.61. The steep decline stemmed from disappointing Q2 fiscal 2026 results released before the market open, highlighting execution shortfalls and softer demand.

Earnings Results

Azenta reported Q2 revenue from continuing operations of $145 million, up just 1% year-over-year but down 3% organically after adjusting for foreign exchange and the UK Biocentre acquisition. This fell short of analyst expectations of $148.75 million. Non-GAAP diluted EPS came in at a loss of $0.04, missing forecasts of $0.11 and reversing the prior year's $0.01 profit. Adjusted EBITDA dropped 36% to $8 million, with margins contracting 320 basis points to 5.4% due to lower fixed-cost absorption, Automated Stores rework costs, and inventory reserves.

The results reflected cautious demand, particularly in North America, with declines in Sanger Sequencing for Multiomics and core products like Automated Stores and Cryogenic Systems in Sample Management Solutions. A massive $149 million non-cash goodwill impairment—$112.4 million in Multiomics and $36.6 million in Sample Management—further pressured GAAP earnings, leading to an operating loss of $165.8 million.

Guidance Cut

Compounding the miss, Azenta slashed its FY2026 outlook. Total reported revenue is now projected at $603–$621 million, with organic growth revised to -2% to +1% from prior 3–5% growth. Sample Management faces low-single-digit growth instead of mid-single-digits, while Multiomics shifts to mid-single-digit decline. Adjusted EBITDA margins are expected down 125 bps to flat, versus prior expansion guidance. Free cash flow outlook softened to 10–15% improvement. Management cited execution gaps and demand caution, prompting leadership changes and operational focus.

Market Context and Trading Activity

Volume spiked to 964,691 shares, above the average of approximately 900,000, signaling heightened investor reaction to the earnings disappointment. The plunge diverged from broader indices, which ended modestly lower, and biotech peers tracked by ETFs like IBB and XBI, which posted smaller losses. AZTA breached key technical support near $23–$24, its recent moving averages, and the 52-week low around $19.87, accelerating downside momentum in the healthcare equipment sector.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI-driven trading bots under current market conditions. Tickeron offers hundreds of AI bots scanning thousands of tickers across diverse strategies, timeframes, and performance metrics, from momentum and mean reversion to sector-specific plays. The curated trending section highlights only the strongest live performers, helping traders identify tools with proven edge amid volatility like today’s biotech sell-off. Explore these bots for automated insights on AZTA and peers—elevate your strategy with data-backed automation today.

What Comes Next for AZTA

Investors will monitor Azenta’s progress on operational execution, including Multiomics transformation, leadership enhancements, and cost discipline. Upcoming Q3 fiscal 2026 earnings, expected in early August, represent a key test of demand recovery and guidance delivery. Analyst consensus holds an Outperform rating with a $35–$41 average target, though recent cuts reflect caution. Sector risks include biotech funding pressures and economic sensitivity, while opportunities lie in recurring revenues from sample repositories and consumables. Uncertainties around B Medical Systems divestiture and long-range plan extension to 2029 add layers to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

A.I.Advisor
a Summary for AZTA with price predictions
Jun 05, 2026

AZTA in upward trend: price rose above 50-day moving average on May 28, 2026

AZTA moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 20, 2026. You may want to consider a long position or call options on AZTA as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AZTA just turned positive on May 22, 2026. Looking at past instances where AZTA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for AZTA crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AZTA moved out of overbought territory on June 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AZTA broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AZTA entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.673) is normal, around the industry mean (4.655). P/E Ratio (42.431) is within average values for comparable stocks, (175.074). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.491). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (1.752) is also within normal values, averaging (75.925).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Dividends

AZTA paid dividends on December 23, 2021

Azenta AZTA Stock Dividends
А dividend of $0.10 per share was paid with a record date of December 23, 2021, and an ex-dividend date of December 02, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 7.68B. The market cap for tickers in the group ranges from 126 to 149.48B. ISRG holds the highest valuation in this group at 149.48B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -3%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was -14%. MMED experienced the highest price growth at 18%, while NYXH experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -43%. For the same stocks of the Industry, the average monthly volume growth was -64% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: 29 (-100 ... +100)
View a ticker or compare two or three
AZTA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of automation, vacuum and instrumentation solutions

Industry PharmaceuticalsOther

Profile
Details
Industry
Electronic Production Equipment
Address
200 Summit Drive
Phone
+1 888 229-3682
Employees
3000
Web
https://www.azenta.com
Why Is Azenta (AZTA) Stock Down -23.82% Today?